Evogene

Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, Industrial Applications, and Human Health. The Agriculture segment develops seed traits, agrochemical products, and agro biological products to improve plant performance. The Industrial Applications focuses on the development and commercialization of improved castor bean seeds for industrial uses. The Human Health segment involves discovery and development of human microbiome-based therapeutics. The company was founded by Amir Barzilay and Hagai Karchi on October 10, 1999 and is headquartered in Rehovot, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Evogene reports revenue growth and strategic collaborations driving future prospects

Evogene's Q1 2024 performance showed revenue growth, decreased losses, and strategic milestones achieved by key subsidiaries.
The company's strengths lie in innovative collaborations, a unique CPB platform, and successful revenue-driving partnerships.
Challenges include financial management, operational execution, and logistical considerations for seed supply.
Opportunities for growth stem from promising future achievements, strategic partnerships, and market differentiation through innovation.

Evogene reports revenue surge and promising developments in key segments

Evogene demonstrated strong revenue growth in the first half of 2024 and made progress in reducing losses, reflecting improving financial performance.
Casterra's expanding market reach and revenue growth opportunities, coupled with Biomica's promising trial results, position Evogene well for future growth.
While facing challenges in achieving profitability and managing cash flow, Evogene's focus on operational efficiency and market expansion presents avenues for sustainable growth.

Evogene reports Q3 revenue decline but anticipates growth opportunities

Evogene's Q3 2024 performance reflected a decline in revenues but improved cost management, with a focus on enhancing cash reserves.
The company's strengths lie in upcoming revenue growth, strategic collaborations, and plans to fortify its financial position.
Challenges include market uncertainties, operational losses, and addressing investor concerns for sustained growth and profitability.
Opportunities exist for Evogene to capitalize on its achievements, explore new avenues, and drive value creation for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Conference call and webcast: today, May 18, 2023, 9:00 am ET REHOVOT, Israel , May 18, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, today announced its financial results for the first quarter period ending March 31, 2023.

Evogene Reports First Quarter 2023 Financial Results

The grant under the EU Horizon Program was approved following the successful proof of concept from the previous program launched in 2016 REHOVOT, Israel , May 9, 2023 /PRNewswire/ -- The Ag-Seed Division of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) ("Evogene"), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments has announced that it has been granted a prestigious EU Horizon grant of €1.2 million, to support the creation of oil-seed crops that have high carbon-dioxide assimilation and enhanced drought tolerance.

Evogene Ag-Seed Division Awarded Prestigious €1.2M Horizon Grant to Develop Oil-Seed Crops with High CO2 Assimilation and Drought Tolerance

Conference call scheduled for 9AM ET REHOVOT, Israel , May 4, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development, announced today that it will release its financial results for the first quarter of 2023, on Thursday, May 18, 2023.

Evogene Schedules First Quarter 2023 Financial Results Release & Conference Call for May 18, 2023

REHOVOT and MOSHAV KESHET, Israel , May 2, 2023 /PRNewswire/ -- Canonic Ltd. ("Canonic"), focused on the development of medical grade cannabis products and a wholly owned subsidiary of Evogene Ltd.

Plantis Licenses Two of Canonic's Proprietary Cannabis Varieties to Expand its Offerings in the Israeli Market

REHOVOT, Israel , April 27, 2023 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.

Biomica Announces Closing of $20 Million Financing Round led by Shanghai Healthcare Capital

REHOVOT, Israel , March 29, 2023 /PRNewswire/ -- Lavie Bio Ltd. ("Lavie Bio"), a subsidiary of Evogene Ltd.

Lavie Bio Announces Appointment of Amit Noam as its Incoming Chief Executive Officer

REHOVOT, Israel , March 15, 2023 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.

Biomica VP R&D to Present at the Pharmabiotics 2023 Conference on March 21, 2023

Evogene Ltd. (NASDAQ:EVGN ) Q4 2022 Earnings Conference Call March 9, 2023 9:00 AM ET Company Participants Ofer Haviv - Chief Executive Officer Eyal Ronen - Executive Vice President, Business Development Yaron Eldad - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Brett Reiss - Janney Montgomery Scott Brian Wright - ROTH Capital Operator Ladies and gentlemen, thank you for standing by.

Evogene Ltd. (EVGN) Q4 2022 Earnings Call Transcript

Evogene (EVGN) delivered earnings and revenue surprises of 66.67% and 20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Evogene (EVGN) Reports Q4 Loss, Tops Revenue Estimates

Conference call and webcast: today, March 9, 2023, 9:00 am ET REHOVOT, Israel , March 9, 2023 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, today announced its financial results for the fourth quarter and full year period ending December 31, 2022.

Evogene Reports Fourth Quarter and Full Year 2022 Financial Results

REHOVOT, Israel , March 6, 2023 /PRNewswire/ --  Lavie Bio Ltd., a subsidiary of Evogene Ltd.

Lavie Bio to Host a Round Table Discussion and is a Sponsor at World Agri-Tech Conference in San Francisco

REHOVOT, Israel , March 6, 2023 /PRNewswire/ -- Ag Plenus Ltd., an innovative company designing effective, sustainable crop protection products by leveraging computational biology and chemistry, and a subsidiary of Evogene Ltd.

AgPlenus to Attend World Agri-Tech Conference in San Francisco

REHOVOT, Israel , March 1, 2023 /PRNewswire/ -- Biomica, a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced it will be presenting at the 2023 ECCO Annual Meeting taking place in Copenhagen, Denmark from March 1 to 4, 2023.

Biomica CSO to Present at the ECCO 2023 Annual Meeting in Copenhagen between March 1-4, 2023

REHOVOT, Israel , March 1, 2023 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, today announced that it will attend and meeting with investors at the 35th Annual ROTH Conference being held in Dana Point, California on March 13-14, 2023.

Evogene to Attend the Annual ROTH Investor Conference in California on March 13, 2023

Positive results for LAV311 and LAV321 achieved in 2022 in a series of field trials, testing for protection against bunch rot, powdery mildew and blight diseases REHOVOT, Israel , Feb. 28, 2023 /PRNewswire/ -- Lavie Bio Ltd., a subsidiary of Evogene Ltd.

Lavie Bio Reports Successful Results for its Bio-Fungicides Programs

Conference call scheduled for 9am ET REHOVOT, Israel , Feb. 27, 2023 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development announced today that it will release its financial results for the fourth quarter and full year 2022 on Thursday, March 9, 2023.

Evogene Schedules Fourth Quarter and Full Year 2022 Financial Results Release & Conference Call for March 9, 2023

Evogene's subsidiary Casterra has developed proprietary genomically modified, high-yield & high oil-content Castor seed varieties. In September 2022 the EU banned palm oil and soybean as a biofuel or biodiesel feedstock beginning 2023 through to 2030. Castor oil is a replacement.

Evogene Subsidiary Casterra Ag: Castor Seeds Benefiting From Changes In EU Laws

Second-generation products were developed using novel genetic markers and leverages Evogene's GeneRator AI tech-engine  REHOVOT, Israel , Feb. 21, 2023 /PRNewswire/ -- Canonic Ltd., focused on the development of medical grade cannabis products and a wholly owned subsidiary of Evogene Ltd.

Canonic Successfully Launched Six Second-Generation Cannabis Products with Higher THC and Rich Terpene Profiles

REHOVOT, Israel , Jan. 24, 2023 /PRNewswire/ --  Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.

Biomica CEO to Participate in Panel Discussion at 7th European Annual Microbiome Movement

Casterra to sell its unique castor seed varieties and provide its significant experience in castor cultivation, for the biofuel production of one of the world's major energy companies REHOVOT, Israel , Jan. 19, 2023 /PRNewswire/ -- Casterra Ag Ltd. ("Casterra"), the integrated castor cultivation solution company and a subsidiary of Evogene Ltd.

Casterra Announces Agreement with World Leading Energy Company to Cultivate its Castor Varieties at Commercial Scale

Evogene (EVGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About Evogene (EVGN) Rating Upgrade to Strong Buy

REHOVOT, Israel , Dec. 28, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.

Biomica CEO to Attend the JP Morgan Healthcare Week in San Francisco between January 9-11, 2023

InflaRx

LianBio

Merck

Pfizer

Sichuan Kelun-Biotech will partner seven preclinical antibody-drug conjugate assets with Merck in a deal that pays Kelun-Biotech $175 million upfront and up to $9.3 billion in milestones - the third ADC deal between the two companies this year. LianBio announced that Pfizer will exercise an option to develop and commercialize a novel respiratory syncytial virus (RSV) therapy candidate in Greater China.

Week In Review: Kelun-Biotech In $9.5 Billion ADC Deal With Merck

Funding round led by Shanghai Healthcare Capital  REHOVOT, Israel , Dec. 21, 2022 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.

Biomica Raises $20 Million in a Financing Round to Advance its Pipeline of Microbiome-based Therapeutics

REHOVOT, Israel , Dec. 8, 2022 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) (the "Company", "Evogene"), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today that Bayer will pay Evogene an amount of $3.5 million under their joint seed traits collaboration agreement.

News for Evogene Stock (EVGN)